Auteurs

Dr. Manja Epping

Associé

Read More

Dr. Anja Lunze, LL.M.

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More

Judith Krens

Associé

Read More
Auteurs

Dr. Manja Epping

Associé

Read More

Dr. Anja Lunze, LL.M.

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More

Judith Krens

Associé

Read More

29 avril 2020 |

Everything biologic and biosimilar in-house counsel need to know about COVID-19

In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.

In this session we focussed on critical developments impacting biologic and biosimilar companies, including:

  • regulatory responses and challenges in the US and Europe
  • changes in patent office policies and proceedings
  • developments in the court systems, and
  • dealing with contractual and supply chain issues.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
Sciences de la vie et Santé

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 juillet 2020
QUICK READ

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

The Bolar and related exemptions in Europe

What activity do they cover?

5 mars 2020

par plusieurs auteurs

Cliquer ici pour en savoir plus

Événements connexes